Hans van Eenennaam, Ph.D. has been promoted executive vice president antibody research and site head of Aduro Biotech Europe. In his new role, Dr. van Eenennaam will lead antibody research and oversee the company’s day to day operations. Prior to its acquisition by Aduro in 2015, Dr. van Eenennaam served as chief operating officer of BioNovion, a company he co-founded in 2011 focused on the development of therapeutic antibodies in the field of immuno-oncology. Earlier in his career, he held n...